Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2012-001324-34-BE
EUCTR2012-001324-34-BEActive, not recruitingNot Applicable

A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients - Travoprost 0.004% in Pediatric Glaucoma Patients

Alcon Research Ltd0 sites130 target enrollmentStarted: February 5, 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
130
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Patients 2 months to <18 years of age
  • •2. Diagnosis of pediatric glaucoma
  • •3. Patients with conditions requiring chronic treatment with glucocorticoids resulting in steroid induced glaucoma may be enrolled as long as the patient has been on a stable dose of steroids for at least 30 days prior to the Screening Visit.
  • •4. Qualifying mean IOP at the Eligibility Visit in at least one eye must be:
  • •= 20 mmHg at the 9 AM (± 60 minutes) time point
  • •Note: Mean IOP is the average of 2 successive IOP measurements in the same eye, as described in the Manual of Procedures. A third measurement is required if the first 2 measurements differ by more than 4 mmHg.
  • •5. Aphakic patients with contact lenses may be enrolled. If study drops are to be instilled with lens in place, patient will be
  • •provided with a contact lens to be used during the study.
  • •6. Written informed consent, including assent when applicable, MUST be obtained from the parent or legally authorized
  • •representative prior to any procedure specified in the protocol, including screening procedures.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 130
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. Females of childbearing potential are excluded from participation in the study if they meet any of the following conditions:
  • •a. They are currently pregnant
  • •b. They have a positive result on a pregnancy test at the Screening Visit
  • •c. They intend to become pregnant during the study period
  • •d. They are breast feeding
  • •e. They are not using any of the following highly effective birth control measures:
  • •True abstinence – when this is in line with the preferred and usual lifestyle of the subject. If subjects become sexually active, they must agree to use one of the birth control methods (hormonal, mechanical, or
  • •surgical) listed below for the remainder of the study.
  • •Hormonal – implanted contraceptives.
  • •Mechanical –IUD with progestogen.
  • •Surgical – vasectomized partner (must be = 6 months post vasectomy).
  • •Note: All females of childbearing potential must consent to a urine pregnancy test at the Screening Visit and upon exiting the study.
  • •Note: Females of childbearing potential will be instructed to immediately inform the Investigator if they become pregnant during the study. Should this occur, the
  • •Investigator shall immediately contact the Sponsor).
  • •2. Patients who have previously failed long-term treatment with a prostaglandin analog or timolol to control IOP or patients in
  • •which reasonable IOP control would not be expected from pharmacological treatment.
  • •3. History of chronic, recurrent or severe inflammatory eye disease (ie, scleritis, uveitis, herpes keratitis).
  • •4. Ocular trauma requiring medical attention within the past 3 months prior to the Screening Visit.
  • •5. Ocular infection or ocular inflammation within the past 30 days prior to the Screening Visit.
  • •6. Clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment in the study eye.
  • •7. Severe ocular pathology (including severe dry eye) in the opinion of the Investigator that would preclude the
  • •administration of a topical prostaglandin analog or a topical beta-blocker.
  • •8. Intraocular surgery within the past 30 days in the study eye prior to the Screening Visit.
  • •9. Any abnormality preventing reliable applanation tonometry, including a history of penetrating keratoplasty.
  • •10. Patients with a history of previous cyclodestructive procedure.
  • •11. Any other conditions including severe illness which would make the patient, in the opinion of the Investigator, unsuitable
  • •for the study.
  • •12. Hypersensitivity to any component of the study medications, including medications administered during study exams, in the opinion of the Investigator.
  • •13. History of congenital cardiovascular anomalies or abnormalities which would preclude the safe administration of
  • •a topical beta-blocker. In the event that the effects of the study medications are unclear, the patient may participate with
  • •written approval from the patient’s cardiologist.
  • •There is a potential for additive effects resulting in hypotension and/or marked bradycardia when eye drops with
  • •timolol are administered concomitantly with oral calcium channel blockers, quanethidine or beta-blocking agents, antiarrhythmics,
  • •digitalis glycosides or parasympathomimetics.
  • •The hypertensive reaction to sudden withdrawal of clonidine or can be potentiated when taking beta-blockers. Potentates systemic beta-blockade (e.g. decreased heart rate) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, cimetidine) and timolol. Beta-bloc

Investigators

Similar Trials

Withdrawn
Phase 3
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patientsraised intra-ocular pressure with optic nerve damage10018307
NL-OMON38960Alcon Laboratories5
Active, not recruiting
Phase 1
Travoprost 0.004% in Pediatric Glaucoma PatientsPediatric glaucomaelevated intraocular pressure
EUCTR2012-001324-34-NLAlcon Research Ltd130
Active, not recruiting
Not Applicable
Travoprost 0.004% in Pediatric Glaucoma PatientsPediatric glaucomaelevated intraocular pressure
EUCTR2012-001324-34-ESAlcon Research Ltd130
Active, not recruiting
Not Applicable
Travoprost 0.004% in Pediatric Glaucoma PatientsPediatric glaucomaelevated intraocular pressure
EUCTR2012-001324-34-GBAlcon Research Ltd130
Active, not recruiting
Not Applicable
Travoprost 0.004% in Pediatric Glaucoma Patients
EUCTR2012-001324-34-PTAlcon Research Ltd130